Compare LODE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | CGEN |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | LODE | CGEN |
|---|---|---|
| Price | $3.62 | $1.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.2M | 458.5K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,778,445.00 | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,798.62 | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.99 | N/A |
| 52 Week Low | $1.67 | $1.13 |
| 52 Week High | $6.13 | $2.66 |
| Indicator | LODE | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 55.37 |
| Support Level | $3.81 | $1.43 |
| Resistance Level | $4.10 | $1.73 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.19 | 67.83 |
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.